Daily reminder:

Biomarkers can help doctors identify targeted therapies for specific types of cancer, yet many patients with non-small cell lung cancer aren’t tested for biomarkers. Read about a new program by Amgen to help more patients gain access to testing. #KnowYourBiomarker #NSCLC

Excited to share our plasma only (tumor uninformed) approach to MRD in #crcsm as a contrast to tumor informed approaches. Can’t compare apples to apples with this limited data set but important nonetheless and sets the stage for future work clincancerres.aacrjournals.org/content/early/…

Biomarker Testing For Patients With Advanced Colorectal Cancer Read more: bit.ly/2S2xZMM #ClearYourView #CRC #ColorectalCancer

Virtual Tumor Boards demonstrates feasibility and benefits! The catalyst for improving cancer care outcomes!

As an oncology focused education company whose mission is to enhance the level of cancer care around the world, we love the work advocacy groups do everyday for patients. Visit us at precisca.com to find out more about our patient cancer journey series!

FLASCO Disparities in Cancer Care and Health Equity Summit off to a great start with a high-level overview on #HealthcareDisparities by Luis E Raez and a more holistic lens of #Intersectionality offered by Taofeek K Owonikoko #HemeOncFellowship #LCAM

“We spend trillions of dollars a year in healthcare and patients are still struggling to get bus fare”great discussion on social determinants this morning

Dr. Mohammad Jahanzeb, MD, FACP one of our managing partners and oncology superstar, speaks with Linda Ruschau from PatientPoint on #patientexperience, the power of #tech in the physician office, and much more! linkedin.com/posts/patientp… For more precisca.com

PrecisCa is proud to announce the acceptance of our abstract at SABCS 2021. Visit our blog to learn about our study discussing the positive impact of virtual multidisciplinary tumor boards on patient care: precisca.com/blog/20 #oncology #breastcancer #SABCS SABCS

"The rapid pace of innovation makes it challenging for community practices that are already under time pressure to keep up with new discoveries and targeted therapies." Go to precisca.com/blog/18 and check out our most recent blog post #precisionmedicine #precisca #oncology

We are proud to present our #SABCS21 Abstract on the feasibility and perceived benefit of a virtual tumor board! Learn more about the story behind the study at precisca.com/blog/20 #breastcancer #oncology #cancereducation #SABCS21 #virtualtumorboards #precisca

PrecisCa Mohammad Jahanzeb Naomi Dempsey, MD Appreciated the conversation with Mohammad Jahanzeb regarding the VMTB model PrecisCa is creating. Beyond having some fabulous oncologists on board, this is nuanced virtual model that includes the patient in the conversation. Looking forward to hearing/seeing more. #SABCS21

“I believe we must keep marching forward. But we must move forward with deliberate, coordinated efforts to minimize the emergence of disparities and to shorten the period where only some people benefit.” -Dr. Richard Wender Penn Medicine #PreventCancerDialogue

Was so happy to be back at ASCO this year with my team PrecisCa. If we didn’t get to connect, reach out! Our company goal is to make cancer expertise accessible to all and we are looking for partners to help educate patients and providers

Proud to be supporting the Prevent Cancer Foundation meeting #PreventCancerDialogue We can all advance health equity through innovation

Wonderful discussion with Tennessee Oncology on EOM led by Dr. Stephen Schleicher TennesseeOncology @OBRtweets #oncology #EOM

Having an awesome educational dinner here in Nashville and now presenting on Clinical Trials and the Impact on VBC is David R. Spigel, MD, FASCO

The U.S. FDA has approved the combination of the checkpoint inhibitors #tremelimumab (Imjudo) and durvalumab (Imfinzi) as a first-line treatment for unresectable hepatocellular carcinoma. This is the first FDA approval for tremelimumab, an anti-CTLA-4 drug. bit.ly/3N2Uf1v

Can't wait to see everyone at ASH 2022 this weekend. Let me know if you will be attending and have time to meet. Let's talk 2023 digital media and peer to peer programming or just grab a drink! #ASH2022